Market Overview: Tech Takes a Hit While Healthcare Holds Strong

The market turbulence kept rolling last week, with the tech sector taking the brunt of the damage. The Nasdaq closed down 2.74%, dragging the Dow Jones Industrial Average and S&P 500 lower by 1.91% and 1.94%, respectively. It's been a rough ride for anyone overweight in technology names.

The silver lining? Healthcare continues its impressive rotation, accelerating as really the only sector serving up abundant and attractive opportunities right now. Even with that bright spot, this selloff is starting to look stretched. We're due for a bounce, and it could come sooner than you think.

Crypto, on the other hand, has some serious issues to work through. We're at a make-or-break point, and the next few weeks will tell us whether digital assets can hold key support levels or if there's more pain ahead.

Three Stocks Positioned for Significant Upside

Dianthus Therapeutics: Targeting a 95% Return

What's Happening with Dianthus

Dianthus Therapeutics Inc. (DNTH) is a clinical-stage biotechnology company making waves in the complement system space. They're developing novel monoclonal antibodies aimed at severe autoimmune and inflammatory diseases, giving investors exposure to the rapidly expanding immunology and precision medicine sector. Their lead candidate, DNTH103, targets conditions like generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.

The latest quarterly numbers showed revenue of $396,000 alongside a loss of $36.77 million. This is typical for a clinical-stage biotech burning cash on development.

The valuation metrics are eye-popping in all the wrong ways on the surface. Price-to-Sales sits at a whopping 486.21, and Book Value comes in at just 12.75. These numbers look abysmal if you're hunting for value in traditional terms, but that's not really the game with early-stage biotech.

From a technical standpoint, DNTH just broke out from a wedge pattern. This type of formation typically signals a big acceleration in upside momentum is coming.

Why Dianthus Could Deliver Big Returns

Dianthus Therapeutics is pioneering next-generation complement therapeutics for severe autoimmune diseases. Their lead candidate DNTH103 is a highly potent, selective monoclonal antibody advancing rapidly through multiple Phase 2 trials in underserved neuromuscular conditions like generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). This innovative approach targets the root cause of inflammation with subcutaneous dosing every two weeks, addressing critical unmet needs in markets projected to exceed $10 billion by 2030. It positions Dianthus as a potential leader in precision immunology.

The breakthrough Phase 2 data from the MaGic trial in gMG underscores DNTH103's best-in-class potential. The results demonstrated robust efficacy in reducing symptoms and improving quality of life for patients with limited treatment options. With enrollment exceeding targets at 65 patients and top-line results released in September 2025, this milestone validates the program's scientific foundation and accelerates the path to Phase 3. It's building a narrative of transformative impact in rare disease care.

Strategic pipeline acceleration in CIDP and multifocal motor neuropathy is building out a neuromuscular franchise with multiple catalysts through year-end 2026. The proactive launch of a potentially registrational CIDP study, alongside ongoing trials, diversifies revenue prospects across high-value indications. This creates a robust development roadmap that de-risks execution and taps into growing demand for complement-targeted therapies in immunology.

Strong institutional momentum reflects growing confidence in Dianthus's trajectory. Prominent biotech investors like Baker Bros. Advisors and Braidwell LP added or maintained positions in Q3 2025 13F filings. This influx of sophisticated capital, alongside a $150 million public offering in September 2025, bolsters the company's financial runway into 2027. It enables aggressive advancement without dilution pressures and signals undervalued potential in the biotech sector.

The analyst community is backing this story. HC Wainwright rates it a Buy, Wedbush has it at Outperform, and Truist Securities also rates it a Buy. When you see this kind of consensus among biotech analysts, it's worth paying attention.

The Action Plan for Dianthus (95% Return Potential)

I'm bullish on DNTH above the $35.00-$36.00 range. My upside target sits at $80.00-$82.00, which represents approximately 95% return potential from current levels.

Daqo New Energy: Riding the Solar Wave for 78% Gains

What's Happening with Daqo

Daqo New Energy Corp. (DQ) is a leading manufacturer of high-purity polysilicon, which is a critical raw material for solar photovoltaic products. This gives investors direct exposure to the rapidly growing renewable energy and solar power sector, with a focus on advanced production processes and global sustainability initiatives.

The last quarterly report showed revenue of $244.60 million but no earnings. That's not unusual in the solar materials space, where pricing volatility can swing margins dramatically quarter to quarter.

Valuation looks pretty strong in DQ relative to peers. Price-to-Sales comes in around 3.60, but Book Value is 64.93, suggesting the stock is trading on sale compared to its net asset value.

From a technical perspective, DQ just broke out from an ascending triangle formation. This is a continuation pattern that signals the uptrend is back in effect and likely to accelerate.

Why Daqo Is Positioned for a Strong Run

Daqo New Energy Corp. is riding the global solar power surge as a leading polysilicon producer. Its high-purity materials fuel the photovoltaic supply chain amid accelerating renewable energy adoption worldwide. As governments and corporations commit to net-zero goals, Daqo's established production capacity positions it to benefit from the explosive growth in solar installations, projected to exceed 1 TW annually by 2030. This creates a resilient narrative of essential infrastructure in the clean energy transition.

Operational resilience and cost efficiencies highlight Daqo's competitive edge in a volatile market. Despite industry headwinds, the company's focus on low-cost production in China has sustained profitability. Q2 2025 results showcased disciplined execution and a path to stabilizing margins as polysilicon prices recover, reinforcing its story as a battle-tested player ready to capitalize on the long-term upcycle in solar demand.

Strategic expansion into wafers diversifies Daqo's revenue beyond polysilicon, tapping into higher-value segments of the PV ecosystem. The Polysilicon and Wafer segments enable vertical integration, reducing exposure to raw material price swings while capturing more of the value chain. This positions the company for enhanced growth as module manufacturers seek reliable, end-to-end suppliers in a fragmented market.

Geopolitical neutrality and global supply role strengthen Daqo's international appeal. By serving photovoltaic manufacturers across Asia, Europe, and North America, the company navigates trade tensions through a diversified customer base and technology leadership. It's building a narrative of indispensable reliability in the quest for energy independence and sustainable power solutions.

Analyst coverage reflects mixed but increasingly positive sentiment. Roth Capital has a Neutral rating, while Citigroup and GLJ Research both rate it a Buy.

The Action Plan for Daqo (78% Return Potential)

I'm bullish on DQ above $27.00-$28.00. My upside target is $50.00-$52.00, representing roughly 78% return potential from entry levels.

Arcus Biosciences: Cancer Immunotherapy Play with 45% Upside

What's Happening with Arcus

Arcus Biosciences, Inc. (RCUS) is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for cancer and inflammatory diseases. It offers investors exposure to the rapidly growing oncology and immunology sector, with a focus on innovative treatments like domvanalimab and casdatifan for lung cancer and renal cell carcinoma.

The company shared revenue of $26 million in their latest quarter, but still posted a loss of $135 million. Again, this is par for the course in clinical-stage biotech where R&D spending dominates the P&L.

Valuation in RCUS is sky-high by traditional metrics. Price-to-Sales sits at 8.38 and Book Value is just 3.52. But if the clinical data continues to impress, these numbers won't matter much.

From a charting perspective, RCUS is consolidating its recent gains within a rectangle pattern. This type of consolidation typically points to more upside once the pattern resolves with a breakout.

Why Arcus Has Room to Run

Arcus Biosciences Inc. is advancing its innovative TIGIT pathway inhibitors to transform cancer immunotherapy. Domvanalimab plus zimberelimab demonstrated superior efficacy in Phase 3 NSCLC trials, reducing progression risk by 37% versus pembrolizumab alone. This breakthrough positions Arcus as a frontrunner in a $50 billion-plus immuno-oncology market, addressing resistance challenges in lung cancer and unlocking potential for broader solid tumor applications amid surging demand for next-gen therapies.

The casdatifan program's late-stage momentum fuels Arcus's oncology pipeline growth. With Phase 3 initiation in clear cell renal cell carcinoma (ccRCC) backed by compelling Phase 1b data showing 80% response rates in combination with cabozantinib, casdatifan offers best-in-class HIF-2α inhibition. This taps into a $10 billion RCC market and creates a narrative of precision medicine leadership for genetically driven cancers.

Strategic collaborations with AstraZeneca and Gilead amplify Arcus's global reach and validation. The expanded AstraZeneca partnership for Phase 3 trials in NSCLC and RCC, alongside Gilead's $1.5 billion TIGIT option exercise, provide non-dilutive funding and co-development firepower. This reinforces Arcus's story as a biotech innovator with de-risked assets and accelerated paths to commercialization in high-unmet-need indications.

Robust financial position post-offering supports aggressive pipeline execution. The November 2025 completion of a $269.7 million stock offering extends Arcus's cash runway into 2028, funding multiple Phase 3 readouts and new indications without immediate dilution pressures. This positions the company to navigate biotech volatility while capitalizing on clinical catalysts in 2026.

Analyst coverage shows growing support. Goldman Sachs maintains a Neutral rating, while Citigroup and HC Wainwright both rate it a Buy.

The Action Plan for Arcus (45% Return Potential)

I'm bullish on RCUS above $17.00-$17.50. My upside target is $32.00-$33.00, offering approximately 45% return potential.

Market-Moving Catalysts for the Week Ahead

Holiday Trading Season Arrives with Seasonal Tailwinds

We're entering one of the most bullish periods of the year from a seasonal standpoint. The back half of November has historically been one of the strongest times for equity markets, and after the turbulence of recent weeks, bulls have something concrete to look forward to.

But this isn't all there is to anticipate this week. The Thanksgiving holiday arrives on Thursday here in the United States. It's a day to give thanks for all that we have, but in reality, we should be practicing gratitude much more often than just for a single day.

Over the years, I've found it increasingly important to take these rest days when they come. With 24-hour trading coming in the future, we're going to have to find ways to unplug from the markets. That reset is key for keeping a clear and level head when you're back at the screen.

Could a Dollar Rebound in 2026 Boost Stocks?

A rebound in the U.S. dollar during 2026 could prove bullish for domestic stocks by easing several headwinds that weighed on markets in 2025. A stronger dollar typically signals improving U.S. growth expectations and attractive interest-rate differentials, encouraging foreign capital inflows into U.S. assets and supporting higher equity valuations.

It also allows the Federal Reserve to keep cutting rates without fears of currency collapse or imported inflation. For U.S.-centric companies (which dominate the S&P 500), a firmer dollar reduces the translation drag on foreign earnings and calms concerns about competitive devaluation abroad.

Perhaps most importantly, an orderly dollar recovery often coincides with "U.S. exceptionalism" regimes in which domestic stocks outperform global peers. This attracts even more allocation toward U.S. equities and creates a self-reinforcing bullish cycle that can last for quarters or even years.

Sector and Industry Strength: Healthcare Takes the Crown

This is the biggest shift I've seen at a sector level in months. Going back to the start of Q3, we now see healthcare (XLV) as the undisputed leader in the S&P 500, while technology (XLK) has dropped down to third place. That's a remarkable reversal.

Utilities (XLU) are holding up in second place, so we now have a situation where two defensive sectors—healthcare and utilities—are outperforming. This is not a strong signal for bulls in the near term. Defensive leadership typically emerges when investors are nervous about growth prospects.

Bulls can rest on the fact that staples (XLP) are still near the bottom of the pack. It wouldn't take much of a rebound in tech to bring it back into first place. But for now, we're better off exercising patience and waiting for clearer signals.

Looking across different timeframes, healthcare has been the consistent leader. Over one week, three weeks, 13 weeks, healthcare dominates the top spot. Only when you extend to 26 weeks does technology reclaim the lead. This tells you the rotation has legs, but it's not necessarily a structural shift yet.

Healthcare's momentum keeps accelerating, and that's where the opportunities are most abundant right now.

Is Tech Losing the Plot?

It's no secret that this market lives and dies by the tech sector (XLK). It represents around 30% of the S&P 500, so when this sector isn't rising—and more importantly, isn't outperforming—it's going to cause some serious headwinds for the broader market.

Fortunately, this only looks to be a temporary bump in the road. The trend in the XLK/SPY ratio is very clearly to the upside. It's been making higher highs and higher lows throughout 2025. We even look to be in the process of forming a higher low right here.

Let's not lose sight of the fact that the ratio broke out from a wedge formation back in the summer. This is a momentum pattern, and once this pullback in the ratio is over, I'll be looking for tech to reemerge as the big mover in markets. The fundamentals supporting tech leadership haven't changed. AI spending continues to accelerate, cloud adoption keeps expanding, and productivity gains from technology remain the primary driver of earnings growth across the economy.

Is the U.S. the Place to Be Again?

One of the big themes of 2025 was international stocks outperforming U.S. stocks by a wide margin for the first time in many years. However, with the prospect of a big rebound in the dollar, could we see a reversion back to the trend that's dominated the past several years?

I'm looking at the ratio between the S&P 500 (SPY) and a total world stock fund (VT). The ratio is in a broader uptrend, but over the past couple of years, we've seen it consolidate into a symmetrical triangle formation. This is a continuation pattern that typically resolves in the direction of the prior trend.

I'm watching for a break above the upper trendline of the pattern, as that could lead to a big breakout from the triangle and point to a continuation in the uptrend. This would lead to a major influx of capital back into the U.S. market, potentially fueling a powerful rally in domestic equities while international markets lag.

Stress in Junk Bonds Demands Attention

I want to dive a bit deeper into some key credit ratios, because there's some growing stress that needs to be resolved sooner than later if this rally in stocks is going to continue. Yes, bonds and stocks are connected to one another in a very real way, and ignoring credit markets is a recipe for getting blindsided.

I'm looking at the ratio between junk bonds (HYG) and 3-7 Year Treasuries (IEI). The key here is to see HYG outperform IEI. In other words, junk bonds have to outperform Treasuries. This signals confidence from capital markets and strong liquidity conditions. When investors are willing to reach for yield in lower-quality credits, it means they're comfortable with risk.

The ratio is coming back down after testing resistance of a saucer formation. Bigger picture, I think we will see a big breakout next year, but near term, seeing this ratio drop does raise a cautionary signal. It's probably waiting for a signal from the Fed that rate cuts are still on the table.

My Take on Credit Markets

Junk bonds have a reputation for trading similar to stocks with respect to volatility. That said, they're still higher up on the capital ladder compared to stocks. Bulls need to see this ratio rebound if stocks are going to see a holiday rally worth trading.

The Fed watches ratios like these closely. In theory, rate cuts would help to ease the difficulty in bond markets and give junk bonds a boost. It looks like we got some favorable rhetoric from Fed officials in the past week too, with several speakers suggesting patience on rate hikes and openness to further cuts if inflation continues to moderate.

Cryptocurrency at a Critical Juncture

The downward drift in crypto continued last week, and we're still looking for more concrete signs of a bounce. To be clear, it looks like we're closer to the end of this decline than we are the beginning, but we still need to be alert for wide price swings. Volatility in digital assets can be extreme, especially at inflection points like this.

Since Ethereum lost the key 3200-3300 level of support, it now becomes resistance. There are some serious technical headwinds now that Ethereum is trading below this zone. The next level it may test is in the 2600-2800 zone, which would represent another significant leg down from current prices.

I don't think this changes much for the bigger picture in 2026. In fact, I am looking for Ethereum to be back at new all-time highs in 2026, and even testing the 6,000 zone. But in the short term, we need to see it stabilize and reclaim that 3200-3300 level. Let's see if it can get back into the descending channel soon and start building a base for the next leg higher.

The crypto market has a tendency to move in violent swings, and this pullback could be setting up the next explosive rally. But timing is everything, and right now, patience is the right strategy until we see clearer technical confirmation of a bottom.

Bottom Line: Patience and Preparation

Markets are at an interesting inflection point. The tech selloff looks extended, healthcare is leading with conviction, and we're entering a seasonally strong period. The three stocks highlighted here—Dianthus Therapeutics, Daqo New Energy, and Arcus Biosciences—offer compelling risk/reward setups for investors willing to do their homework and exercise patience on entry points.

The key is waiting for the market to give you the signal. Don't chase. Let the next dip come to you, and be ready to act when it does. With the right preparation and discipline, the coming weeks could offer some of the best buying opportunities we've seen in months.